NCT04018950

Study to Determine the Excretion and Metabolism of 14C-ETX2514 Administered Intravenously in Healthy Male Subjects

Single Period, Open Label, Phase 1 Study to Determine the Excretion and Metabolism of 14C-ETX2514 Administered Intravenously in Healthy Male Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: Entasis Therapeutics · Industry
• Sex: Male
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This study will be conducted to determine the routes and rates of excretion of radio label arising from 14C-ETX2514 and to characterize metabolites of ETX2514 arising from 14C-ETX2514 administered intravenously in healthy participants.

Conditions

• Acinetobacter Baumannii-calcoaceticus Complex Infections

Interventions

Type	Name	Description
DRUG	ETX2514	intravenous infusion
DRUG	14C-ETX2514	intravenous infusion

Timeline

• Start date: 2019-06-21
• Primary completion: 2019-07-26
• Completion: 2019-07-26
• First posted: 2019-07-15
• Last updated: 2019-08-30

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study